Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post‐surgery. Issue 12 (20th July 2017)

• Record Type: Journal Article
• Authors: Breen, Kieran J.; O'Neill, Amanda; Murphy, Lisa; Fan, Yue; Boyce, Susie; Fitzgerald, Noel; Dorris, Emma; Brady, Lauren; Finn, Stephen P.; Hayes, Brian D.; Treacy, Ann; Barrett, Ciara; Aziz, Mardiana Abdul; Kay, Elaine W.; Fitzpatrick, John M.; Watson, R. William G.
• Is Part Of: Prostate. Volume 77:Issue 12(2017)
• Page Start: 1288
• Page End: 1300
• Publication Date: 2017-07-20
• Subjects: AKT -- BCR -- IGF‐1 receptor -- insulin receptor -- PTEN; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23389
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract : Background: Between 20% and 35% of prostate cancer (PCa) patients who undergo treatment with curative intent (ie, surgery or radiation therapy) for localized disease will experience biochemical recurrence (BCR). Alterations in the insulin‐like growth factor (IGF) axis and PTEN expression have been implicated in the development and progression of several human tumors including PCa. We examined the expression of the insulin receptor (INSR), IGF‐1 receptor (IGF‐1R), PTEN, and AKT in radical prostatectomy tissue of patients who developed BCR post‐surgery. Methods: Tissue microarrays (TMA) of 130 patients post‐radical prostatectomy (65 = BCR, 65 = non‐BCR) were stained by immunohistochemistry for INSR, IGF‐1R, PTEN, and AKT using optimized antibody protocols. INSR, IGF1‐R, PTEN, and AKT expression between benign and cancerous tissue, and different Gleason grades was assessed. Kaplan‐Meier survival curves were used to examine the relationship between proteins expression and BCR. Results: INSR ( P < 0.001), IGF‐1R ( P < 0.001), and AKT ( P < 0.05) expression was significantly increased and PTEN ( P < 0.001) was significantly decreased in cancerous versus benign tissue. There was no significant difference in INSR, IGF‐1R, or AKT expression in the cancerous tissue of non‐BCR versus BCR patients ( P = 0.149, P = 0.990, P = 0.399, respectively). There was a significant decrease in PTEN expression in the malignant tissue of BCR versus non‐BCR patients ( P = 0.011). Combinational analysis of the tissue proteins identified a combination of decreased PTEN and increased AKT or increased INSR was associated with worst outcome. We found that in each case, our hypothesized worst group was most likely to experience BCR and this was significant for combinations of PTEN+INSR and PTEN+AKT but not PTEN+IGF‐1R ( P = 0.023, P = 0.028, P = 0.078, respectively). Conclusions: Low PTEN is associated with BCR and this association is strongly modified by high INSR and high AKT expression. Measurement of these proteins could help inform appropriate patient selection for postoperative adjuvant therapy and prevent BCR.